Featured Research

from universities, journals, and other organizations

Researchers identify factors behind blood-making stem cells

Date:
July 9, 2010
Source:
University of Montreal
Summary:
Researchers have made significant progress in the understanding of blood-producing (hematopoietic) stem cells. The study identifies factors that control the production of hematopoietic stem cells and offers interesting insight critical to the development of novel regenerative therapies and treatments for leukemia.

A team of researchers from the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal have made significant progress in the understanding of blood-producing (hematopoietic) stem cells. The study led by IRIC Chief Executive Officer and Scientific Director, Dr. Guy Sauvageau, identifies factors that control the production of hematopoietic stem cells.

Published in the journal Cell Stem Cell, the research offers interesting insight critical to the development of novel regenerative therapies and treatments for leukemia.

Hematopoietic stem cells (HSCs) are located within the bone marrow and serve as a reservoir for the production of all blood cells. A disruption in this process can have dire consequences leading either to a depleted blood cell population which can cause severe immune deficiencies, or excessive proliferation of blood cells which can trigger the development of leukemia. At the moment, relatively little is known about what controls this production.

The current study aims to understand the roles of various proteins that are present in HSCs and their impact on blood production. Researchers found that three proteins (Msi2, Pard6a and Prkcz) help blood cells to regenerate. That is, when HSCs lack these proteins, blood cells have a reduced capacity to regenerate themselves. Results from a fourth protein, Prox1, showed the reverse effect: their presence hinders the reproduction of blood cells.

"Understanding which proteins control the production of blood-making stem cells is crucial knowledge for designing therapies for diseases caused by unruly HSCs" explains Dr. Sauvageau, "Now that we recognize the key roles that these proteins play, we can evaluate their potential as therapeutic targets to treat a variety of diseases such as leukemia."

Dr. Guy Sauvageau holds the Canada Research Chair in the Molecular Genetics of Normal and Cancer Cells. The research received funding from the Canadian Institutes for Health Research.


Story Source:

The above story is based on materials provided by University of Montreal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kristin J. Hope, Sonia Cellot, Stephen B. Ting, Tara MacRae, Nadine Mayotte, Norman N. Iscove, Guy Sauvageau. An RNAi Screen Identifies Msi2 and Prox1 as Having Opposite Roles in the Regulation of Hematopoietic Stem Cell Activity. Cell Stem Cell, 2010; 7 (1): 101 DOI: 10.1016/j.stem.2010.06.007

Cite This Page:

University of Montreal. "Researchers identify factors behind blood-making stem cells." ScienceDaily. ScienceDaily, 9 July 2010. <www.sciencedaily.com/releases/2010/07/100706150620.htm>.
University of Montreal. (2010, July 9). Researchers identify factors behind blood-making stem cells. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/07/100706150620.htm
University of Montreal. "Researchers identify factors behind blood-making stem cells." ScienceDaily. www.sciencedaily.com/releases/2010/07/100706150620.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins